Mobile website
Archive > Volume 20 Issue 5 > 2013,20(5):535-539. DOI:10.3872/j.issn.1007-385X.2013.05.005 Prev Next
Basic Research
Effect of melanoma-associated antigen-A9 on transcriptional activity and function of P53 in human breast cancer MDA-MB-231 cells
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective : To explore the effect of melanoma-associated antigen (MAGE)-A9 on the transcriptional activity and the function of P53. Methods: Plasmids pcDNA3.0, pcDNA3.0-p53 and pCMV6-MAGE-A9 were transfeced in vitro into human breast cancer MDA-MB-231 cells using LipofectamineTM2000. The expressions of p21WAF1 mRNA and protein in MDA-MB-231 cells were analyzed by RT-PCR and Western blotting. Luciferase reporter assay was performed to determine the luciferase activity induced by p21WAF1 promoter in MDA-MB-231 cells. MTT assay were adopted to explore the effect of different plasmids on the cell proliferation. Results: The expression of p21WAF1 both in mRNA and protein levels was decreased in pcDNA3.0-p53/MAGE-A9 group, compared with pcDNA3.0-p53 group (\[0.15±0.01\] vs \[0.18±002\], \[0.03±0.00\] vs \[0.06±0.01\], P<0.05). The luciferase activity induced by p21WAF1 promoter was remarkably increased in MDA-MB-231 cells transfected with plasmid pcDNA3.0-p53 (\[58.56±3.47\] vs \[1.00±012\], P<001). After transfected with pcDNA3.0-p53/MAGE-A9, the luciferase activity induced by p21WAF1 promoter in MDA-MB-231 cells was significantly reduced compared with that in pcDNA3.0-p53 group (\[22.02±4.91\] vs \[58.56±3.47\], P<005). Compared with pcDNA3.0 group, the proliferation rate were significantly decreased in pcDNA3.0-p53 group (\[228.89±22.39\]% vs \[337.23±23.67\]%, P<0.05), while in pcDNA3.0-p53/MAGE-A9 group, it was significantly higher than that in pcDNA3.0-p53 group (\[291.51±5.91\]% vs \[228.89±22.39\]%, P<0.05). Conclusion: MAGE-A9 can inhibit the transcriptional activity of P53 and proliferation of MDA-MB-231 cells.
Keywords:
Project Supported:
Project supported by the Scientific Research Foundation of Health Bureau of Hebei Province (No. 20100120), and the Natural Science Foundation of Hebei Province (No. H2012206077)
Clc Number:
